ATE239484T1 - Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen - Google Patents

Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen

Info

Publication number: ATE239484T1
Authority: AT; Austria
Prior art keywords: nucleoside; substituent; molecule; linking group; soluble vitamin
Prior art date: 1991-10-24

Application number

AT92923139T

Other languages

English (en)

Inventor

Muthiah Manoharan

Philip Dan Cook

Clarence Frank Bennett

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-24

Filing date

1992-10-23

Publication date

2003-05-15

1992-10-23 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE239484T1 publication Critical patent/ATE239484T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
238000010521 absorption reaction Methods 0.000 title 1
239000002777 nucleoside Substances 0.000 abstract 9
150000003833 nucleoside derivatives Chemical class 0.000 abstract 4
125000003835 nucleoside group Chemical group 0.000 abstract 4
125000001424 substituent group Chemical group 0.000 abstract 3
-1 aromatic lipophilic molecule Chemical class 0.000 abstract 2
125000005647 linker group Chemical group 0.000 abstract 2
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 abstract 2
239000011782 vitamin Substances 0.000 abstract 2
229940088594 vitamin Drugs 0.000 abstract 2
229930003231 vitamin Natural products 0.000 abstract 2
235000013343 vitamin Nutrition 0.000 abstract 2
150000003722 vitamin derivatives Chemical class 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
230000004700 cellular uptake Effects 0.000 abstract 1
239000002738 chelating agent Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
239000000138 intercalating agent Substances 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
150000004032 porphyrins Chemical class 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT92923139T 1991-10-24 1992-10-23 Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen ATE239484T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US78237491A	1991-10-24	1991-10-24
PCT/US1992/009196 WO1993007883A1 (en)	1991-10-24	1992-10-23	Derivatized oligonucleotides having improved uptake and other properties

Publications (1)

Publication Number	Publication Date
ATE239484T1 true ATE239484T1 (de)	2003-05-15

Family

ID=25125854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92923139T ATE239484T1 (de)	1991-10-24	1992-10-23	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen

Country Status (7)

Country	Link
EP (2)	EP1331011A3 (de)
JP (1)	JP2823959B2 (de)
AT (1)	ATE239484T1 (de)
AU (1)	AU2916292A (de)
CA (1)	CA2122030C (de)
DE (1)	DE69233046T2 (de)
WO (1)	WO1993007883A1 (de)

Families Citing this family (230)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5688488A (en) *	1989-04-03	1997-11-18	Purdue Research Foundation	Composition and method for tumor imaging
US5457189A (en) *	1989-12-04	1995-10-10	Isis Pharmaceuticals	Antisense oligonucleotide inhibition of papillomavirus
US6395492B1 (en)	1990-01-11	2002-05-28	Isis Pharmaceuticals, Inc.	Derivatized oligonucleotides having improved uptake and other properties
US5578718A (en) *	1990-01-11	1996-11-26	Isis Pharmaceuticals, Inc.	Thiol-derivatized nucleosides
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US6114513A (en) *	1990-01-11	2000-09-05	Isis Pharmaceuticals, Inc.	Thiol-derivatized oligonucleotides
US6060592A (en)	1990-01-11	2000-05-09	Isis Pharmaceuticals, Inc.	Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5688941A (en) *	1990-07-27	1997-11-18	Isis Pharmaceuticals, Inc.	Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5608046A (en) *	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5998603A (en) *	1994-09-29	1999-12-07	Isis Pharmaceuticals, Inc.	4'-desmethyl nucleoside analogs, and oligomers thereof
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US7223833B1 (en)	1991-05-24	2007-05-29	Isis Pharmaceuticals, Inc.	Peptide nucleic acid conjugates
US6713602B1 (en)	1991-05-24	2004-03-30	Ole Buchardt	Synthetic procedures for peptide nucleic acids
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US5607691A (en) *	1992-06-12	1997-03-04	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
US6071699A (en)	1996-06-07	2000-06-06	California Institute Of Technology	Nucleic acid mediated electron transfer
US6184389B1 (en)	1994-01-11	2001-02-06	Isis Pharmaceuticals, Inc.	Combinatorial libraries having aminodiol monomer subunits
US6828427B1 (en)	1994-01-11	2004-12-07	Isis Pharmaceuticals, Inc.	Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same
US6448373B1 (en)	1994-01-11	2002-09-10	Isis Pharmaceuticals, Inc.	Phosphate linked oligomers formed of monomeric diols and processes for preparing same
US5886177A (en) *	1994-01-11	1999-03-23	Isis Pharmaceuticals, Inc.	Phosphate linked oligomers
US5637684A (en) *	1994-02-23	1997-06-10	Isis Pharmaceuticals, Inc.	Phosphoramidate and phosphorothioamidate oligomeric compounds
US5646269A (en) *	1994-04-28	1997-07-08	Gilead Sciences, Inc.	Method for oligonucleotide analog synthesis
US6468981B1 (en) *	1994-07-29	2002-10-22	Emory University	Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
AUPM747694A0 (en) *	1994-08-16	1994-09-08	Commonwealth Scientific And Industrial Research Organisation	Delivery of nucleic acids and peptides
FR2727970A1 (fr) *	1994-12-12	1996-06-14	Inst Nat Sante Rech Med	Conjugues fullerene-oligonucleotide, ou fullerene-nucleotide leurs complexes avec des nanoparticules et leurs utilisations therapeutiques
AU5359496A (en) *	1995-03-06	1996-09-23	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6242434B1 (en)	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
US5855911A (en)	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997023497A1 (en) *	1995-12-22	1997-07-03	University Technologies International Inc.	Linker arm for solid support oligonucleotide synthesis and process for production thereof
US5834198A (en) *	1996-03-21	1998-11-10	Boehringer Mamnnheim Gmbh	Selective photoinducted flavin-dependent cleavage of RNA at G-U base pairs and kits therefor
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
DE69725440T2 (de)	1996-06-06	2004-07-22	Novartis Ag	2-substituierte nukleosid- und oligonukleotid- derivate
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US6977244B2 (en)	1996-10-04	2005-12-20	Board Of Regents, The University Of Texas Systems	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0856579A1 (de)	1997-01-31	1998-08-05	BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH	Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
JP2001511811A (ja) *	1997-02-13	2001-08-14	ボーンケアインターナショナルインコーポレイテッド	ビタミンｄ化合物の標的治療放出
US6127533A (en)	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6191273B1 (en)	1997-09-05	2001-02-20	Isis Pharmaceuticals, Inc.	Substituted cyclic compounds and mixtures comprising same
US7572582B2 (en)	1997-09-12	2009-08-11	Exiqon A/S	Oligonucleotide analogues
US7704962B1 (en)	1997-10-03	2010-04-27	Board Of Regents, The University Of Texas System	Small oligonucleotides with anti-tumor activity
US7285288B1 (en)	1997-10-03	2007-10-23	Board Of Regents, The University Of Texas System	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6232463B1 (en)	1997-10-09	2001-05-15	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
AU4328399A (en) *	1998-06-15	2000-01-05	Alza Corporation	Nucleic acid-cobalamin complexes and their use in gene therapy
EP1091972A1 (de) *	1998-07-02	2001-04-18	University Technologies International Inc.	Wiederverwendbarer festträger für oligonukleotid-synthese
WO2000001393A2 (en) *	1998-07-02	2000-01-13	The Trustees Of Columbia University In The City Of New York	OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6277967B1 (en)	1998-07-14	2001-08-21	Isis Pharmaceuticals, Inc.	Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
SE9803099D0 (sv) *	1998-09-13	1998-09-13	Karolinska Innovations Ab	Nucleic acid transfer
US6403779B1 (en)	1999-01-08	2002-06-11	Isis Pharmaceuticals, Inc.	Regioselective synthesis of 2′-O-modified nucleosides
EP1178999B1 (de)	1999-05-04	2007-03-14	Santaris Pharma A/S	L-ribo-lna analoge
US6656730B1 (en) *	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6277982B1 (en)	1999-08-20	2001-08-21	Isis Pharmaceuticals, Inc.	Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
EP1301479A2 (de)	2000-07-18	2003-04-16	Bone Care International, Inc.	Stabilisiertes 1alpha-hydroxy vitamin d
US6809195B1 (en)	2000-08-16	2004-10-26	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotides
DE10048091A1 (de) *	2000-09-28	2002-04-25	Ernst Bayer	Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
US7662767B2 (en)	2000-12-06	2010-02-16	Materials Evolution And Development Usa, Inc.	Polynucleotide intercalator interceptors and inhibitors
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US6878805B2 (en)	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
US7148211B2 (en)	2002-09-18	2006-12-12	Genzyme Corporation	Formulation for lipophilic agents
EP2290100B1 (de) *	2002-11-01	2014-02-19	Iris International, Inc.	Kit für Verdrängungs-Sandwich-Immuno-PCR
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US6913890B2 (en)	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
AU2004263830B2 (en)	2003-06-13	2008-12-18	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US7674778B2 (en) *	2004-04-30	2010-03-09	Alnylam Pharmaceuticals	Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7094775B2 (en)	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
AU2005328382C1 (en)	2004-07-21	2013-01-24	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a modified or non-natural nucleobase
CA2574603C (en) *	2004-08-04	2014-11-04	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
CN103091485A (zh)	2004-11-03	2013-05-08	艾瑞斯国际有限公司	用于亲和分离的微泡
DE602005023529D1 (de)	2004-11-03	2010-10-21	Iris Molecular Diagnostics Inc	Homogener nachweis von analyten
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007051045A2 (en)	2005-10-28	2007-05-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
EP1942948A4 (de)	2005-11-04	2010-03-03	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
CA2626690A1 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
EP1984499B1 (de)	2006-01-27	2015-05-27	Isis Pharmaceuticals, Inc.	Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulation von mikro-rnas
ES2874149T3 (es)	2006-05-11	2021-11-04	Alnylam Pharmaceuticals Inc	Composiciones y métodos para inhibir la expresión del gen PCSK9
AU2007299629C1 (en)	2006-09-21	2012-05-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the HAMP gene
EP3192788A1 (de)	2006-10-03	2017-07-19	Arbutus Biopharma Corporation	Lipidhaltige formulierungen
US8507200B2 (en)	2007-02-09	2013-08-13	Northwestern University	Particles for detecting intracellular targets
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
DK2160464T3 (da)	2007-05-30	2014-08-04	Univ Northwestern	Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
ES2428009T3 (es)	2007-07-05	2013-11-05	Novartis Ag	ARNds para tratar infecciones virales
CN101970662A (zh) *	2007-11-05	2011-02-09	波罗的科技发展有限公司	带有修饰碱基的寡核苷酸作为抗病毒剂的应用
FR2931152B1 (fr) *	2008-05-16	2010-07-30	Centre Nat Rech Scient	Nouveau systeme de transfert d'acide nucleique
CN106955360A (zh)	2008-11-24	2017-07-18	西北大学	多价rna纳米颗粒组合物
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010211133A1 (en)	2009-02-03	2011-07-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of PTP1B genes
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20130079382A1 (en)	2009-10-12	2013-03-28	Larry J. Smith	Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
DK2494075T3 (en)	2009-10-30	2018-07-23	Univ Northwestern	TABLE-MANAGED NANOCONJUGATES
US20110112176A1 (en)	2009-11-09	2011-05-12	John Frederick Boylan	Compositions and methods for inhibiting expression of kif10 genes
US20110152349A1 (en)	2009-12-18	2011-06-23	Anke Geick	Compositions and methods for inhibiting expression of il-18 genes
US20110196016A1 (en)	2010-02-05	2011-08-11	Anke Geick	Compositions and Methods for Inhibiting Expression of IKK2 Genes
EP3210611B1 (de)	2010-03-12	2019-08-21	The Brigham and Women's Hospital, Inc.	Verfahren zur behandlung von gefässentzündungserkrankungen
RS56011B1 (sr)	2010-04-29	2017-09-29	Ionis Pharmaceuticals Inc	Modulacija ekspresije transtiretina
EP2630240A1 (de)	2010-10-18	2013-08-28	Arrowhead Research Corporation	Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
HRP20181564T1 (hr)	2011-06-30	2018-11-30	Arrowhead Pharmaceuticals, Inc.	Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
US9889209B2 (en)	2011-09-14	2018-02-13	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
EP3597741A1 (de)	2012-04-27	2020-01-22	Duke University	Genetische korrektur mutierter gene
CN108524919A (zh)	2012-05-17	2018-09-14	延伸生物科学股份有限公司	用于改进的药物递送的载体
US10077443B2 (en)	2012-11-15	2018-09-18	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugates
CN104955952A (zh)	2013-01-30	2015-09-30	弗·哈夫曼-拉罗切有限公司	Lna寡核苷酸碳水化合物缀合物
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
ES2770667T3 (es)	2013-06-27	2020-07-02	Roche Innovation Ct Copenhagen As	Oligómeros antisentido y conjugados que se dirigen a PCSK9
WO2015042466A2 (en)	2013-09-19	2015-03-26	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Compositions and methods for inhibiting jc virus (jcv)
EP3052627B1 (de)	2013-10-04	2018-08-22	Novartis AG	Neuartige formate für organische verbindungen zur verwendung bei rna-interferenz
EP3052107B1 (de)	2013-10-04	2018-05-02	Novartis AG	Organische verbindungen zur behandlung von hepatitis-b-infektionen
JP6694811B2 (ja)	2013-10-04	2020-05-20	ノバルティスアーゲー	ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
US9789197B2 (en)	2014-10-22	2017-10-17	Extend Biosciences, Inc.	RNAi vitamin D conjugates
WO2016065052A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Insulin vitamin d conjugates
US9585934B2 (en)	2014-10-22	2017-03-07	Extend Biosciences, Inc.	Therapeutic vitamin D conjugates
KR20170078843A (ko)	2014-11-21	2017-07-07	노오쓰웨스턴 유니버시티	구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
US10676726B2 (en)	2015-02-09	2020-06-09	Duke University	Compositions and methods for epigenome editing
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
KR20180038465A (ko)	2015-08-07	2018-04-16	애로우헤드 파마슈티컬스 인코포레이티드	Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
AU2016349954B2 (en)	2015-11-05	2022-08-25	Antisense Therapeutics Ltd	Mobilizing leukemia cells
CA2999649A1 (en)	2015-11-06	2017-05-11	Crispr Therapeutics Ag	Materials and methods for treatment of glycogen storage disease type 1a
HUE067905T2 (hu)	2015-11-12	2024-11-28	Hoffmann La Roche	Oligonukleotidok paternális UBE3A expresszió indukálására
AU2016355178B9 (en)	2015-11-19	2019-05-30	Massachusetts Institute Of Technology	Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
EA201891317A3 (ru)	2015-11-30	2019-04-30	Дьюк Юниверсити	Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
CA3006618A1 (en)	2015-12-01	2017-06-08	Crispr Therapeutics Ag	Materials and methods for treatment of alpha-1 antitrypsin deficiency
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
KR20250065735A (ko)	2016-03-14	2025-05-13	에프. 호프만-라 로슈 아게	Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US20190127736A1 (en)	2016-04-29	2019-05-02	Aptamir Therapeutics, Inc.	Inhibition of mir-22 mirna by apt-110
CN109414448B (zh)	2016-06-17	2021-10-26	豪夫迈·罗氏有限公司	用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
CN109310765A (zh)	2016-06-20	2019-02-05	领先基因生物技术股份有限公司	抗体-药物偶联物
EP3475424A1 (de)	2016-06-22	2019-05-01	ProQR Therapeutics II B.V.	Einzelsträngige oligonukleotide zur rna-editierung
WO2018002762A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP3478828B1 (de)	2016-06-29	2024-09-04	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von friedreich-ataxie und anderen verwandten erkrankungen
JP7305534B2 (ja)	2016-07-06	2023-07-10	バーテックスファーマシューティカルズインコーポレイテッド	疼痛関連障害を処置するための物質及び方法
AU2017292173B2 (en)	2016-07-06	2022-01-13	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
WO2018017754A1 (en)	2016-07-19	2018-01-25	Duke University	Therapeutic applications of cpf1-based genome editing
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JOP20190015A1 (ar)	2016-08-04	2019-02-04	Arrowhead Pharmaceuticals Inc	عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
US10941402B2 (en)	2016-09-01	2021-03-09	Proqr Therapeutics Ii B.V.	Chemically modified single-stranded RNA-editing oligonucleotides
JP7206214B2 (ja)	2016-12-13	2023-01-17	シアトルチルドレンズホスピタル（ディービーエイシアトルチルドレンズリサーチインスティテュート）	インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
BR112019014282A2 (pt)	2017-01-10	2020-03-03	Arrowhead Pharmaceuticals, Inc.	Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
US20190367920A1 (en)	2017-01-13	2019-12-05	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb1 expression
US20190345495A1 (en)	2017-01-13	2019-11-14	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb2 expression
WO2018130585A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating relb expression
US20200216845A1 (en)	2017-01-13	2020-07-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rela expression
WO2018130582A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rel expression
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
US11559588B2 (en)	2017-02-22	2023-01-24	Crispr Therapeutics Ag	Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
JP2020508056A (ja)	2017-02-22	2020-03-19	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	遺伝子編集のための組成物および方法
WO2018154462A2 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2019030313A2 (en)	2017-08-11	2019-02-14	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019038228A1 (en)	2017-08-22	2019-02-28	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
CN111226114A (zh)	2017-10-13	2020-06-02	罗氏创新中心哥本哈根有限公司	用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
UA126931C2 (uk)	2017-10-16	2023-02-22	Ф. Хоффманн-Ля Рош Аг	МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
MA50877A (fr)	2017-11-21	2020-09-30	Bayer Healthcare Llc	Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
PT3717646T (pt)	2017-12-01	2025-07-28	Texas A & M Univ Sys	Tratamento antisense da síndrome de angelman
US20200385714A1 (en)	2017-12-11	2020-12-10	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en)	2017-12-12	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating rb1 expression
WO2019123429A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a
JP2021507253A (ja)	2017-12-21	2021-02-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｈｔｒａ１ｒｎａアンタゴニストについてのコンパニオン診断
WO2019122279A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Oligonucleotides comprising a phosphorodithioate internucleoside linkage
CN111448316B (zh)	2017-12-22	2025-02-14	罗氏创新中心哥本哈根有限公司	新的硫代亚磷酰胺
WO2019122282A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
US20210095274A1 (en)	2018-01-10	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating pias4 expression
BR112020013994A2 (pt)	2018-01-12	2020-12-08	Bristol-Myers Squibb Company	Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
AU2019207859A1 (en)	2018-01-12	2020-07-02	Roche Innovation Center Copenhagen A/S	Alpha-synuclein antisense oligonucleotides and uses thereof
EA202091693A1 (ru)	2018-01-12	2021-04-14	Бристол-Маерс Сквибб Компани	Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
US20210095275A1 (en)	2018-01-12	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating gsk3b expression
CN111615558A (zh)	2018-01-17	2020-09-01	罗氏创新中心哥本哈根有限公司	用于调节erc1表达的寡核苷酸
WO2019144061A1 (en)	2018-01-19	2019-07-25	Duke University	Genome engineering with crispr-cas systems in eukaryotes
WO2019145386A1 (en)	2018-01-26	2019-08-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating csnk1d expression
KR20200140805A (ko)	2018-02-21	2020-12-16	브리스톨-마이어스 스큅 컴퍼니	Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도
JP7550648B2 (ja)	2018-03-19	2024-09-13	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
MA52661A (fr)	2018-04-05	2021-02-17	Centre Leon Berard	Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
CA3091490A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
GB201808146D0 (en)	2018-05-18	2018-07-11	Proqr Therapeutics Ii Bv	Stereospecific Linkages in RNA Editing Oligonucleotides
SG11202012759XA (en)	2018-07-03	2021-01-28	Hoffmann La Roche	Oligonucleotides for modulating tau expression
EP4512407A3 (de)	2018-07-13	2025-09-24	F. Hoffmann-La Roche AG	Oligonukleotide zur modulation der stel1-expression
EP3830101B1 (de)	2018-07-31	2025-11-19	Roche Innovation Center Copenhagen A/S	Oligonukleotide mit einer phosphordithioat-internukleosid-verknüpfung
US20210292358A1 (en)	2018-07-31	2021-09-23	Roche Innovation Center Copenhagen A/S	Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
CA3130431A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Phosphonoacetate gapmer oligonucleotides
WO2020169696A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Novel phosphoramidites
US20220177894A1 (en)	2019-04-02	2022-06-09	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for immunotherapy
KR20210149107A (ko)	2019-04-03	2021-12-08	브리스톨-마이어스 스큅 컴퍼니	Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
MX2021015003A (es)	2019-06-06	2022-01-24	Arrowhead Pharmaceuticals Inc	Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
CA3143679A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
KR20220042116A (ko)	2019-06-18	2022-04-04	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
CN114729392A (zh)	2019-09-06	2022-07-08	10X基因组学有限公司	用于对细胞和细胞珠粒进行条形码化的系统和方法
WO2021122944A1 (en)	2019-12-18	2021-06-24	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
WO2022175815A1 (en)	2021-02-19	2022-08-25	Pfizer Inc.	Methods of protecting rna
EP4301856A2 (de)	2021-03-05	2024-01-10	ProQR Therapeutics II B.V.	Antisense-oligonukleotide zur verwendung bei der behandlung von hornhautdystrophien
PE20240696A1 (es)	2021-03-08	2024-04-10	Servier Lab	Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
CN113274492B (zh) *	2021-05-21	2022-06-17	大连理工大学	一种基于羟基氧化铝纳米羧基改性的复合疫苗佐剂的制备方法
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
US20240376473A1 (en)	2021-09-16	2024-11-14	Qmine Co., Ltd.	Antisense compound for modulating wfdc2 expression
IL311855A (en)	2021-10-08	2024-05-01	Pfizer	Immunogenic lnp compositions and methods thereof
WO2023089556A1 (en)	2021-11-22	2023-05-25	Pfizer Inc.	Reducing risk of antigen mimicry in immunogenic medicaments
EP4448106A1 (de)	2021-12-17	2024-10-23	Hoffmann-La Roche Inc.	Kombination von oligonukleotiden zur modulierung von stel1 und fubp1
EP4453196A1 (de)	2021-12-21	2024-10-30	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
EP4469079A1 (de)	2022-01-28	2024-12-04	Pfizer Inc.	Coronavirus-antigenvarianten
WO2023166425A1 (en)	2022-03-01	2023-09-07	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023233290A1 (en)	2022-05-31	2023-12-07	Janssen Sciences Ireland Unlimited Company	Rnai agents targeting pd-l1
WO2024028794A1 (en)	2022-08-02	2024-02-08	Temple Therapeutics BV	Methods for treating endometrial and ovarian hyperproliferative disorders
US20260014279A1 (en)	2022-09-16	2026-01-15	Alia Therapeutics Srl	Enqp type cas proteins and applications thereof
EP4593867A2 (de)	2022-09-30	2025-08-06	Extend Biosciences, Inc.	Langwirkendes parathormon
WO2024105162A1 (en)	2022-11-16	2024-05-23	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
EP4637717A1 (de)	2022-12-23	2025-10-29	Pfizer Inc.	Lipidpartikelzusammensetzungen und verfahren zur verwendung davon
CN120882867A (zh)	2023-01-11	2025-10-31	阿利亚治疗有限公司	Ii型cas蛋白及其应用
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2025036916A1 (en)	2023-08-16	2025-02-20	Les Laboratoires Servier	Oligonucleotides for modulating kcnt1 expression
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025248505A1 (en)	2024-05-31	2025-12-04	Wayne State University	Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
AU651569B2 (en) *	1990-01-11	1994-07-28	Isis Pharmaceuticals, Inc.	Compositions and methods for detecting and modulating RNA activity and gene expression
WO1995006659A1 (en) *	1992-07-01	1995-03-09	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
CA2079109A1 (en) *	1990-03-29	1991-09-30	John A. Latham	Oligonucleotide-transport agent disulfide conjugates
AU4848793A (en) *	1992-09-11	1994-04-12	Isis Pharmaceuticals, Inc.	Oligonucleotide and nucleotide amine analogs, methods of synthesis and use

1992
- 1992-10-23 WO PCT/US1992/009196 patent/WO1993007883A1/en not_active Ceased
- 1992-10-23 EP EP03076286A patent/EP1331011A3/de not_active Withdrawn
- 1992-10-23 DE DE69233046T patent/DE69233046T2/de not_active Expired - Lifetime
- 1992-10-23 JP JP5507961A patent/JP2823959B2/ja not_active Expired - Fee Related
- 1992-10-23 AU AU29162/92A patent/AU2916292A/en not_active Abandoned
- 1992-10-23 CA CA002122030A patent/CA2122030C/en not_active Expired - Lifetime
- 1992-10-23 EP EP92923139A patent/EP0724447B1/de not_active Expired - Lifetime
- 1992-10-23 AT AT92923139T patent/ATE239484T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0724447A1 (de)	1996-08-07
JP2823959B2 (ja)	1998-11-11
EP1331011A3 (de)	2003-12-17
CA2122030C (en)	1997-03-04
EP1331011A2 (de)	2003-07-30
JPH06510791A (ja)	1994-12-01
CA2122030A1 (en)	1993-04-29
WO1993007883A1 (en)	1993-04-29
EP0724447B1 (de)	2003-05-07
EP0724447A4 (de)	1996-01-22
DE69233046T2 (de)	2004-03-04
DE69233046D1 (de)	2003-06-12
AU2916292A (en)	1993-05-21

Legal Events

Date	Code	Title	Description
2003-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE239484T1 (de)	2003-05-15	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
DE69434299T2 (de)	2006-06-14	Thiol-derivatisierte Nukleoside und Oligonukleoside
MX160856A (es)	1990-06-05	Mejoras en mecanismo diferencial para vehiculos
ATE133713T1 (de)	1996-02-15	Nukleinsäuremultimere und amplifizierte nukleinsäurehybridisierungstests damit
WO1991012023A3 (en)	1991-11-14	Hybrid reagents capable of selectively releasing molecules into cells
NO996107L (no)	2000-02-10	C-4"-substituerte makrolidderivater
ATE138691T1 (de)	1996-06-15	Verbesserte nukleinsäure-hybridisierungstests für hbv, die amplifikation verwenden
DE69714600T2 (de)	2003-03-27	Verfahren zur markierung von nukleotiden, markierte nukleotide und nuetzliche zwischenprodukte
MX9203504A (es)	1992-07-01	Complejo agente: lipido activo de alta proporcion.
IT1226825B (it)	1991-02-19	Derivati 4' fosfato di glucosidi della epipodofillotossina e relative composizioni farmaceutiche.
FI880405A7 (fi)	1988-08-05	Adenosin-5'-karboxamidderivat.
MX9303708A (es)	1994-05-31	Proceso de glucosilacion anionica estereoselectiva para preparar 2'-desoxifluoro-beta nucleosidos.
WO1990015159A3 (en)	1991-06-27	Nucleic acid probes for the detection of chlamydia trachomatis
ES2186008T3 (es)	2003-05-01	Colorantes de reticulocito excitables por helio-neon y derivables de halolepidinas.
KR920012106A (ko)	1992-07-25	표지된 변형 올리고뉴클레오티드
ATE141926T1 (de)	1996-09-15	Neue cobalamin-säurehydrazide und davon abgeleitete cobalamin-konjugate
KR920701220A (ko)	1992-08-11	신규의 복핵 백금 착체 및 이를 유효성분으로하는 항종양제
IE45070L (en)	1977-11-30	Anthracycline glycoside antibiotics
DE4239531A1 (de)	1994-05-26	Reagenz zur Kupplung verschiedener Substanzen an Nukleinsäuren sowie Verfahren zu dessen Herstellung
Meyer et al.	1996	Synthesis and characterization of a new 5-thiol-protected deoxyuridine phosphoramidite for site-specific modification of DNA
AU2739797A (en)	1997-11-26	(in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides
IT1308393B1 (it)	2001-12-17	Supporto per barra (e) con alloggiamento (i) in grado di riceverebarre di sezioni trasversali differenti.
WO1998004575A3 (en)	1998-03-19	Lipophilic oligonucleotide analogs
IT8621205A0 (it)	1986-07-22	Supporto pieghevole per impedire lo spostamento di corpi rotolanti, in particolare ruote di veicoli.
Edge et al.	1972	Synthetic analogues of polynucleotides. Part VIII. Analogues of oligonucleotides containing carboxymethylthymidine